Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Truist Securities maintains a Buy rating on Sutro Biopharma (NASDAQ:STRO) but lowers the price target from $18 to $15.
August 16, 2024 | 4:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities maintains a Buy rating on Sutro Biopharma but lowers the price target from $18 to $15.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100